Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation

Nephron

Volumn 72, Issue 3, 1996, Pages 483-

  Fehrman Ekholm, Ingela ^a   Jogestrand, Tomas ^a   Angelin, Bo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GEMFIBROZIL;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION; LETTER; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTILIPEMIC AGENTS; CYCLOSPORINE; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 0030064726     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188918     Document Type: Article

References (2)

1. Dimeny E. Tufveson G. Larsson E, Siegbahn A. Fcllstrom B: The influence of pre-transplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993: 23:572-579.
2. Lindholm A. Henricsson S: Intra-and interindividual variability in the free fraction of cyclosporine in plasma in recipients of renal transplants. Thcr Drug Monit 1989:11:623-630.